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Abstract
Background: Bubonic plague is the primary manifestation of infection with Yersinia pestis, accounting for 90% of all
plague cases and with 75% of global cases reported in Madagascar. All drugs in use for treating plague are registered
based on experimental data and anecdotal evidence, and no regimen currently recommended is supported by a
randomized clinical trial. The IMASOY trial intends to fill this knowledge gap by comparing two 10-day regimens
included in the national guidelines in Madagascar. The primary objective of the trial is to test the hypothesis that
ciprofloxacin monotherapy is non-inferior to streptomycin followed by ciprofloxacin for the treatment of bubonic
plague, thus avoiding the need for injectable, potentially toxic, aminoglycosides.
Methods: A two-arm parallel-group randomized control trial will be conducted across peripheral health centres in
Madagascar in five districts. Males and non-pregnant females of all ages with suspected bubonic or pneumonic plague
will be recruited over the course of three plague ‘seasons’. The primary endpoint of the trial is to assess the proportion
of patients with bubonic plague who have a therapeutic response to treatment (defined as alive, resolution of fever,
25% reduction in the size of measurable buboes, has not received an alternative treatment and no clinical decision to
continue antibiotics) as assessed on day 11.
Discussion: If successful, the trial has the potential to inform the standard of care guidelines not just in Madagascar
but in other countries afflicted by plague. The trial is currently ongoing and expected to complete recruitment in 2022.
Trial registration: ClinicalTrials.gov NCT04110340. Registered on 1 October 2019
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Introduction
Background and rationale {6a}
Plague
Plague is caused by the Gram-negative bacteria Yersinia
pestis. There are three main clinical forms in which
plague can manifest, sometimes with overlapping clinical
syndromes: bubonic plague, septicaemic plague (primary
or secondary) and pneumonic plague (primary or sec-
ondary) [1]. Bubonic plague is the most common clinical
form and is characterized by the rapid onset of fever and
tender and painful lymphadenopathy. It accounts for
over 90% of plague cases [1]. Septicaemic plague is char-
acterized by non-specific symptoms, as for septicaemia
in general [1]. Pneumonic plague presents with rapid on-
set of fever and respiratory symptoms, with haemoptysis
being a cardinal feature [1].
Plague is primarily present in Africa, although the
USA and countries in Asia and South America are also
affected. The incidence of plague continues to decrease
(from 2683 cases notified to the WHO in 2008 to 243 in
2018) and geographical spread to shrink (98% of
reported cases currently from just Madagascar and the
Democratic Republic of Congo (DRC)) [2]. However, the
reservoir and conditions for transmission are still
present in many areas of the world, and there is a risk of
outbreaks when plague hits densely populated areas, as
in the 2017 large urban outbreak of predominantly
pneumonic plague in Madagascar, with over 2400
suspected cases [3].
In the pre-antibiotic era, the case fatality rate (CFR) of
plague was > 70% [4]. Antibiotics have significantly re-
duced mortality: for the cases notified to WHO during
2010–2018 CFR averaged 17% [2]. During the 2017–
2018 plague outbreak in Madagascar, the CFR of con-
firmed pneumonic plague was 25% and bubonic plague
24% [3].
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Current treatment options
Until July 2018, the 1st-line treatment regimen for bu-
bonic plague in Madagascar was streptomycin (days 1 to
5) followed by cotrimoxazole (days 3 to 8). Following the
2017 epidemic, an After Action Review was conducted
and treatment guidelines for bubonic plague were modi-
fied to include, for adults, either streptomycin intramus-
cularly 1 g (except pregnant women) or gentamicin 2.5
mg/kg twice daily for 3 days, followed by ciprofloxacin
500 mg twice daily for an additional 7 days or ciprofloxa-
cin alone at 500 mg twice daily for 10 days. Intravenous
ciprofloxacin at a dose of 400 mg every 12 h can be used
if the oral route is not possible. Treatment options in
children are now either oral ciprofloxacin 15mg/kg
twice daily for 10 days or, if oral administration is not
initially possible, streptomycin 15 mg/kg every 12 h
intramuscularly for 3 days followed by ciprofloxacin 15
mg/kg twice daily for an additional 7 days.
The first-line treatment regimen for pneumonic plague
in adults is streptomycin 1 g intramuscularly twice daily
for 5 days combined with ciprofloxacin 500mg orally
twice daily for 10 days, and for children, intravenous
gentamicin at 2.5 mg/kg every 12 h for 5 days (or
streptomycin) combined with oral ciprofloxacin at 15
mg/kg every 12 h for 10 days (with the possibility of
intravenous ciprofloxacin at 15 mg/kg every 12 h if the
oral route is not available). The maximum dose for cip-
rofloxacin is 500 mg per oral dose and 400 mg per intra-
venous dose for children.
Streptomycin alone or in other combination therapies
is also the treatment of choice in other countries,
including the DRC and Peru.
Study rationale
The evidence base for the current treatment regimens for
plague is weak, and none is supported by a randomized
clinical trial (RCT). Two randomized control trials have
previously attempted to improve on or contribute to a
better evidence base for current plague treatment
regimens [5, 6]. However, neither trial was successful nor
included children under 8 years of age, who constitute a
significant proportion of the population affected by
plague. Treatment recommendations are based on animal
models, case reports, case series and a trial of doxycycline
versus gentamicin [5]. All drugs approved for treating
plague by the the United States Food and Drug
Administration (US FDA) (streptomycin, tetracyclines and
the fluoroquinolones ciprofloxacin, levofloxacin and
moxifloxacin) are registered based on the ‘animal efficacy
rule’, in the absence of clinical data [7]. Political instability
and practical difficulties related to highly dispersed cases
in rural areas have been the major obstacles to conducting
treatment trials of plague.
The main issue with current regimens in Madagascar
is the use of aminoglycosides—with the need for
injections, class toxicity and need for monitoring of
renal and auditory functions, which is not routinely
available in most low- and middle-income countries, and
streptomycin cost and stock-outs.
Ciprofloxacin is cheaper, more readily available in low-
and middle-income countries, has greater ease of admin-
istration and there is no need for biochemical or drug
monitoring. There is also no reason to believe that there
is a difference in effectiveness. These reasons would
likely result in ciprofloxacin being the first-line choice
for the treatment of plague should it be shown to be
effective.
Objectives {7}
The primary objective of this trial is to test the
hypothesis that ciprofloxacin monotherapy given (orally,
or for subjects who cannot take oral medications
intravenously or in combination) for 10 days is non-
inferior to streptomycin (given on days 1–3) followed by
ciprofloxacin (given on days 4–10) for the treatment of
bubonic plague. The regimens are respectively third-
and first-line treatments as per the national plague treat-
ment guidelines in Madagascar.
The secondary objective is to collect data on the
effectiveness of ciprofloxacin in the treatment of
pneumonic plague, although the trial is not able to
formally assess the non-inferiority of ciprofloxacin mono-
therapy compared to streptomycin and ciprofloxacin com-
bination therapy in pneumonic plague,
Considering the operational and practical complexities
of a plague RCT, the study also has additional
exploratory objectives to optimize investments: to
evaluate the level and kinetics of anti-Y. pestis antibodies
in bubonic and pneumonic plague during treatment and
follow-up, to compare different methods for detection of
anti-Y. pestis antibodies, to measure the performance of
qPCR for plague diagnosis and to allow for the evalu-
ation of new rapid tests that may become available.
Trial design {8}
Study schematics
This is an individually randomized two-group parallel
arm control trial with a 1:1 ratio. Patients will be ran-
domized to receive either streptomycin + ciprofloxacin
or ciprofloxacin alone. We are using a non-inferiority
design since the overall cure rate for bubonic plague
without septicaemia with streptomycin is expected to be
90%. As a result, demonstrating superiority would be un-
necessary and impractical given the sample size that
would be required. Our aim is therefore to demonstrate
that ciprofloxacin alone is not more than 15% inferior to
streptomycin followed by ciprofloxacin (15% is the non-
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inferiority margin in our study, meaning that the lower
bound of the confidence interval around the risk differ-
ence in the success rates of streptomycin + ciprofloxacin
and ciprofloxacin alone must not include 15%). The trial
is powered for bubonic plague, although we will recruit
patients with pneumonic plague as well.
Box 1—Case definitions
Probable and confirmed cases are defined as:
Probable case: rapid diagnostic test (RDT) or qPCR or serology (anti-F1
IgG ELISA) is positive but without evidence of seroconversion or a
fourfold increase in antibody titre.
Confirmed case: RDT and qPCR are positive, or culture is positive, or
there has been a seroconversion or a fourfold increase in antibody titre
on two separate serological samples (either between D1 and D11,
between D11 and D21 or between D1 and D21).
We will recruit patients with clinical suspicion of
bubonic plague, but the size of our sample is powered
based on an intention to treat infected patient sample size
of 190, where ‘infected’ is defined as a ‘confirmed’ or
‘probable’ case of bubonic plague. As a result, the total
number of patients to be enrolled will be higher than 190.
We estimate that we will need to recruit approximately
600 patients with bubonic plague to achieve a sample size
of 190 confirmed/probable bubonic plague patients.
However, to mitigate risks of being under-powered, we
will recruit for three full seasons (2019–2022) with a mini-
mum target of 190 confirmed/probable cases, 95 patients
in each arm.
Should we achieve the target of 190 confirmed/
probable bubonic plague cases before the end of the
third season (2019–2022), we will nevertheless continue
to recruit until the end of the season to retain power in
the event the observed treatment success rates differ
from those expected, and to allow us to increase
precision.
Whilst we will also recruit and collect data on patients
with pneumonic plague, it is highly unlikely that we will
have the power to complete a non-inferiority trial for
ciprofloxacin monotherapy for pneumonic plague pa-
tients. For example, with a case fatality rate of 20–25%,
we would need a sample size of approximately 400 pa-
tients with probable/confirmed pneumonic plague for a
non-inferiority margin of 15%, which is unrealistic.
Study timelines
Recruitment is expected to last 3 years and will take
place during each ‘plague season’ (the annual high
transmission period of plague, which starts at the
beginning of August and runs until the following
March).
Study population
The study will enrol males and non-pregnant females of
any age with suspected bubonic or pneumonic plague.




The trial will take place in up to five pre-identified dis-
tricts in Madagascar. Madagascar reports more plague
cases per year than any other country with an average
number of confirmed/probable cases per year of 387 [8].
Study sites
Recruitment is planned to take place in 50 health
centres (primary health centres (Centres de Santé de
Base, CSB) and district hospitals) in five districts.
Recruiting districts and sites have been selected based
on their incidence of plague (as reported to IPM) and
also for logistical reasons. However, the trial may be
carried out in further districts or sites depending on the
real-time incidence of suspected cases of plague during
the study period. The majority of plague patients are
treated at the CSB level. In general, CSBs do not have a
laboratory, so sites perform an RDT to obtain a prelim-
inary diagnosis and then send further samples to IPM





 Patients of any age
 Recent onset (< 10 days) of fever (uncorrected
axillary temperature ≥ 37.5 °C) or history of fever
 One or more buboes (tender lymph node swelling)
 Residence or travel to a plague endemic or outbreak
area in Madagascar within 14 days of the onset of
symptoms
 Patients identified as clinically suspected of plague
by health personnel (doctors or paramedics)
Pneumonic plague
 Patients of any age
 Recent onset (< 7 days) of fever (uncorrected axillary
temperature ≥ 37.5 °C) or history of fever
 Cough
 Tachypnoea (respiratory rate > 24 in adults and age-
specific in children)
 Epidemiological link with a confirmed or probable
case of primary or secondary pneumonic plague
within 7 days of onset of symptoms
Randremanana et al. Trials          (2020) 21:722 Page 4 of 15
A small proportion of patients with bubonic plague
will also develop pneumonic plague. These patients will
be randomized to receive pneumonic plague therapy.
For a patient to be considered to have mixed bubonic
and pneumonic plague, they must have developed cough
and dyspnoea after the onset of the bubo.
Exclusion criteria




 Theophylline or warfarin use
 Already treated for bubonic or pneumonic plague in
the preceding 3 months
 Women who report being pregnant
Given that streptomycin is an FDA class D drug,
women who report being pregnant will not be
randomized into the trial but will be treated outside the
trial according to the national guidelines. Lactating
women can safely be treated with streptomycin as
streptomycin poses minimal risk to the infant when used
during breastfeeding and will therefore be randomized
into the trial.
Who will take informed consent? {26a}
All eligible patients will be offered the opportunity to
participate in the study. Patient information sheets,
consent and assent forms will be available in relevant
written local languages. Written informed consent to
participate will be required from all participants or their
representatives and will be requested by local study staff,
who are qualified, trained and authorized to do so by the
principal investigator.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Patients are fully informed about the use of biological
specimens and their data in the patient information
sheet, including lay descriptions of the procedures for
collecting samples and details about data and sample
storage.
Interventions
Explanation for the choice of comparators {6b}
Both treatment regimens tested are provided for by the
national guidelines. There are several reasons why
streptomycin is a suboptimal therapeutic agent for
plague including global stock shortages, the requirement
for parenteral administration and severe toxicity.
In vitro assays suggest that ciprofloxacin has
comparable efficacy to streptomycin and is superior to
doxycycline or gentamicin for the killing of intracellular
Y. pestis [6]. Studies in non-human primates of
pneumonic and bubonic plague have also shown high
therapeutic efficacy of ciprofloxacin, equivalent to
streptomycin [9, 10]. Ciprofloxacin also offers the advan-
tage of the possibility of a switch from intravenous to
oral treatment if clinically appropriate, does not require
drug level or renal function monitoring, has fewer and
less severe side effects, it is classed by the US FDA as
pregnancy category C (whereas other treatment alterna-
tives are category D), has greater global availability and
is cheaper. Unlike other treatment alternatives, cipro-
floxacin can be administered to children.
Intervention description {11a}
Dosing schedule in bubonic plague
Ciprofloxacin arm
 Adults: 500 mg orally twice daily (or 400 mg IV
twice daily for those who cannot take oral
medication) for 10 days.
 Children: 15 mg/kg twice daily (max 500 mg per
dose) orally (or 10 mg/kg IV twice daily for those
who cannot take oral—maximum dose 400 mg) for
10 days.
 Patients who begin intravenous therapy may switch
to oral administration once they are able to swallow
or once deemed clinically appropriate by the
treating physician.
Control arm
 Adults: streptomycin 1 g twice daily for 3 days,
followed by ciprofloxacin 500 mg orally twice daily
(or ciprofloxacin 400 mg twice daily by IV for those
who cannot take it orally) for an additional 7 days.
 Children: streptomycin 15 mg/kg twice daily for
three days followed by ciprofloxacin 15 mg/kg twice
daily (max 500 mg per dose) orally (or 10 mg/kg IV
twice daily for those who cannot take
oral—maximum dose 400 mg) for 7 additional days.
 Patients who start taking intravenous ciprofloxacin
may switch to oral administration once they are able
to swallow or once deemed clinically appropriate by
the treating physician.
Dosing schedule in pneumonic plague
Ciprofloxacin arm
 Adults: 500 mg orally twice daily (or 400 mg IV
twice daily for those who cannot take oral
medication) for 10 days.
 Children: 15 mg/kg twice daily (max 500 mg per
dose) orally (or 10 mg/kg IV twice daily for those
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who cannot take oral—maximum dose 400 mg) for
10 days.
 Patients who begin intravenous therapy may switch
to oral administration once they are able to swallow
or once deemed clinically appropriate by the
treating physician.
Control arm
 Adults: streptomycin 1 g twice daily for 5 days with
ciprofloxacin 500 mg orally twice daily (or
ciprofloxacin 400 mg twice daily IV for those who
cannot take it orally) for 10 days.
 Children: streptomycin 15 mg/kg twice daily for 5
days with ciprofloxacin 15 mg/kg twice daily (max
500 mg per dose) orally (or 10 mg/kg IV twice daily
for those who cannot take it orally—maximum dose
400 mg) for 10 days. This is the alternative treatment
proposed by the Ministry of Public Health since the
2018–2019 plague season.
 Patients who start taking intravenous ciprofloxacin
may switch to oral administration once they are able
to swallow or once deemed clinically appropriate by
the treating physician.
Route of administration
Streptomycin is administered intramuscularly to all
patients in the control group. Ciprofloxacin is
administered orally, except for patients with the
following manifestations:
 Vomiting
 Unable to swallow
 Unconscious
 Systolic blood pressure < 90 mmHg
 Any other conditions or situations for which the
physician decides that intravenous treatment is
indicated
Timing of dosing
 Ciprofloxacin: doses will be administered morning
and evening.
 Streptomycin: doses will be administered morning
and evening.
Duration of therapy
The study drugs will be administered for a total of 10
days. After 10 days, the decision whether to continue
therapy will be at the treating physician’s discretion.
Dosing duration justification
We are using 10 days of therapy in both the
ciprofloxacin arm and streptomycin and ciprofloxacin
arm as this is the current standard duration of plague
treatment in Madagascar. To date, the only RCT in
plague used 7 days of therapy (gentamicin versus




Criteria for discontinuing or modifying allocated
interventions {11b}
If, for any reason, a dose of the study drug is not
administered at the scheduled time, it may be
administered later, but not more than 6 h after the
scheduled time of administration. No dose adjustment is
planned.
Strategies to improve adherence to interventions {11c}
The trial will be co-managed by IPM who will deploy a
clinical research associate and two clinical study nurse
to each district to assist with the recruitment, trial pro-
cedures and data entry. These members of staff will be
based in the districts for the duration of each season.
Before activation, site investigators will receive training
on the identification of plague patients and the study
protocol. After activation, the site investigators will be
responsible for patient management alongside the
clinical study nurse.
To optimize patient compliance, community health
workers (CHWs) in each district will be trained to
identify cases of plague based on community case
definition as per the national guideline, refer patients to
the local CSB I/II, perform treatment visits to patient
homes and complete the treatment record for each
home-based visit. At the time of discharge from the fa-
cility, patients will also be equipped with a mobile
phone, as follow-up visits on D11 and D21, and possibly
M3 will require a return visit to the treating CSB.
At the beginning of each new plague season, all site
staff will be retrained on the trial protocol and
reinitiated to the trial. This will reinforce the protocol
following the annual recruitment suspension and ensure
that, due to high staff turnover at the CSBs, any new
staff members receive the same comprehensive training
as those who were trained at the original initiation visit.
A monitoring plan has been developed to ensure
regular reviews of trial data and site compliance with the
protocol. These reviews will be completed within 72 h of
each of the first five patients being recruited at each site,
annually at the end of each plague season and on the
identification of persistent or serious protocol violations
and serious breaches. The Trial Operations Committee
(TOC) will also meet on a weekly basis to review
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recruitment and compliance and discuss any other
issues affecting the trial.
The trial has also appointed a Data Safety Monitoring
Board (DSMB) and Trial Steering Committee, who will
meet regularly to discuss the management of the trial.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Other treatments, including the administration of fluids
and organ support, will be at the discretion of the
treating clinician.
Provisions for post-trial care {30}
Post-trial care
Following their exit from the trial, patients will return to
their standard care pathway.
Insurance
The University of Oxford, as study sponsor, has
arranged appropriate insurances to provide for the
University’s responsibilities to research subjects and to
cover the legal liabilities of the University to those




The proportion of patients with bubonic plague with a
therapeutic response (assessed on D11). Therapeutic
response is defined as follows for subjects with a visible
and measurable bubo:
 Alive
 Resolution of fever (uncorrected axillary
temperature < 37.5 °C)
 A ≥ 25% decrease in bubo size (in the case of
multiple buboes, the largest bubo)
 Has not received alternative treatment for plague
 No clinical decision to continue anti-plague antibi-
otics beyond day 10
For patients with small buboes that are palpable but
not measurable:
 Alive
 Absence of fever (uncorrected axillary temperature
< 37.5 °C)
 Bubo has not enlarged
 Has not received alternative treatment for plague
 No clinical decision to continue anti-plague antibi-
otics beyond day 10
Secondary endpoints
Bubonic plague
 Proportion of patients without fever (uncorrected
axillary temperature < 37.5 °C) at D4
 Proportion of patients with a pain score < 3 at D4
 Proportion of patients with a pain score < 3 at D11
 Mean % change in bubo size at D4
 Mean % change in bubo size at D11
 Proportion of patients experiencing a serious adverse
event on or before D4
 Proportion of patients experiencing a serious adverse
event on or before D11
 Proportion of patients experiencing a serious adverse
event on or before D21
 Proportion of patients who are fully adherent to the
study treatment schedule
Pneumonic plague
 Proportion of patients with a therapeutic response at
D11. Therapeutic response is defined as follows:
Alive
Resolution of fever (uncorrected axillary
temperature < 37.5 °C)
Resolution of tachypnoea (RR < 24 in adults,
but age-specific in children)
 Proportion of patients without fever (uncorrected
axillary temperature < 37.5 °C) at D4
 Proportion of patients with tachnypnoea resolution
(RR < 24 in adults, but age-specific in children) at D4
 Proportion of patients experiencing a serious adverse
event on or before D4
 Proportion of patients experiencing a serious adverse
event on or before D11
 Proportion of patients experiencing a serious adverse
event on or before D21
 Proportion of patients who fully adhere to the study
treatment schedule
Participant timeline {13}
The participant timeline is described in the flow chart
(Fig. 1).
The schedules of biological procedures, assessments
and samples are summarized in the following tables
(Tables 1 and 2).
The conduct of the study is described in Fig. 2.
The maximum volume of blood to be collected during
the entire duration of the study (3 months) for
confirmed cases with a positive serology at D21 will be
8 ml for children and 16 ml for adults.
Sample size {14}
Assuming that 90% of individuals receiving streptomycin
plus ciprofloxacin (control treatment) meet the primary
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endpoint definition of therapeutic response on day 11,
190 confirmed/probable bubonic plague patients (95 per
group) would be required to have 90% power to
demonstrate the non-inferiority of ciprofloxacin treat-
ment compared to streptomycin plus ciprofloxacin, with
a 15% non-inferiority margin and a one-sided confidence
interval of 2.5%. This calculation takes into account a
10% loss to follow-up rate by the end of treatment. In
total, approximately 600 suspect patients will have to be
recruited to obtain a sample size of 190 confirmed/prob-
able patients.
Table 3 shows the total sample sizes (both arms) for
confirmed/probable bubonic cases to demonstrate non-
inferiority with 90% power, 2.5% one-sided test and
assuming 10% loss to follow up, based on treatment suc-
cess in the streptomycin and ciprofloxacin group and
the non-inferiority margin.
Recruitment {15}
Sites will be geographically spread throughout pre-
identified districts which report a high incidence of
plague. Further districts may be included later in the
trial in the event that they also report a high incidence
of plague.
Whilst it is the responsibility of site medical staff to
assess eligibility and enrol patients, the clinical study
nurse, who will be based within the district, will review
and verify the eligibility of each patient. Community
health workers, who will cover a wider geographical area
within the districts and reach more remote communities,
will also be trained on the protocol and refer suspected
cases of plague to the local CSBs.
Community engagement and outreach
Outreach teams will disseminate health promotion
messages to local health authorities and communities
about plague (i.e. signs and symptoms), as well as the
background and objectives of the trial.
Community health workers will also raise awareness
about going to health centres in the event of suspected
plague.
A social science component will address the practical
aspects and uptake of the trial that may be affected by
the perception of the trial design by both heath care
professionals and patients.
Assignment of interventions: allocation
Sequence generation {16a}
Bubonic or pneumonic plague patients will be
randomized using a computer-generated randomization
sequence generated from the master list, stratified by
health facility and clinical form of the disease (bubonic or
pneumonic plague).
Concealment mechanism {16b}
The allocation sequence was compiled in STATA in a
way that is unpredictable and unreproducible. A copy of
the STATA randomization code file used to compile the
list can be requested from the trial statistician. The trial
statistician will have access and be responsible for the
generation and quality assurance of the randomization
list. This also includes any changes and/or extensions to
Fig. 1 Flow chart demonstrating the participant timeline
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the randomization list and date/s when new any
treatment groups become effective.
Implementation {16c}
The trial statistician has generated the allocation
sequence.
The doctor in-charge at the CSB will confirm the
eligibility of patients with the support of the clinical
study nurse. To randomize patients, the doctor in-charge
will call the clinical research associate who will randomize
the patient on the site’s behalf, informing the site of
the treatment allocation over the phone. Contingency
plans have been put in place to ensure randomization
can take place in the event of internet or mobile signal
outage.
Assignment of interventions: blinding
Who will be blinded {17a}
Blinding of patients and the trial team to treatment
allocation will not be possible due to the different
administration routes of the treatments.
Procedure for unblinding if needed {17b}
Not applicable—this is not a blinded trial.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data will be collected on a paper CRF and then
transferred on to a RedCap database for assessment.
Automatic validations on RedCap will assess data for
completeness and accuracy. A thorough assessment of
data accuracy will be performed via regular monitoring
activities with a focus on primary endpoint data and
safety data, as described in the trial’s monitoring plan.
To validate the methods used to achieve the primary
endpoint (% decrease in bubo size), a pilot study and
training exercise were conducted ahead of activation in
which multiple bubo (real and artificial) measurements
were taken using digital callipers (and ultrasound during
the pilot). The data were used to assess the concordance
of measurements being taken by independent observers.
The percentage difference between the sum of the
longest and shortest axes of measurements taken by two
different clinical study nurse was calculated with an
acceptable margin of 25%. The results showed there was
less than 25% difference between each measurement.
Plans to promote participant retention and complete
follow-up {18b}
Patients will be provided with a mobile phone upon
discharge from the treating centre to optimize retention
Table 2 Assessment schedule
Variables Timing (days)




Plague serology X X X X*
Malaria Ag X
*Only subjects with positive serology on the 21st day will participate in this follow-up
Table 1 Schedule of procedures
Variables Timings (day)




Signs and symptoms X X X X am X X
Vital signs X X X X X X
Doses administered at CSB (am and pm) XX XX XX X am
Doses administered at home (am and pm) X pm XX XX XX XX XX XX
Adverse events X X X X X X
Bubo size and pain score X X X X
Assessments will be done within 24 h of enrolment, depending on the time of admission
M3 3 months after inclusion
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during follow-up. Community health workers will also
assist with reminding patients about their upcoming
follow-up visits.
If a patient chooses to withdraw from trial treatment
(or the treating clinician believes this is in the best
interest of the patient), the patient will continue to
receive the standard of care treatment at the discretion
of their treating clinician, regardless of the treatment
arm to which the patient was randomized. The patient
will remain within the trial for the purpose of follow-up,
data collection, monitoring and data analysis. Healthcare
personnel should explain the importance of allowing
existing data to be used, as well as the importance of
remaining within the trial for follow-up data collection.
If it is not possible to collect further data from the pa-
tient at the scheduled trial visits, routine data should be
collected via the patients’ medical records.
If a patient withdraws their consent to participate in the
trial, data and sample collection will cease and only data
up to the point of withdrawal will be used for analysis.
Fig. 2 Conduct of the study
Table 3 Total sample sizes (both arms) for confirmed/probable bubonic cases
Therapeutic
response*
Margin (%), unilateral confidence interval of 2.5%, loss of 10%, power 90%
5 6 7 8 9 10 11 12 13 14 15
0.95 890 618 454 348 276 224 186 156 134 114 100
0.90 1684 1170 858 658 520 424 350 294 250 216 190
0.85 2384 1656 1216 932 736 596 494 416 354 306 268
0.80 2990 2076 1528 1170 926 750 618 520 444 384 334
0.75 3506 2434 1790 1370 1084 878 726 610 520 450 392
*Proportion of “therapeutic response” in the streptomycin and ciprofloxacin group
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Data management {19}
All data will be recorded on a paper CRF by clinical
study nurses at each study site using a combination of
data directly from patients, patient records and
laboratory results. The clinical study nurses will then
transfer the data from the paper CRF to a RedCap
database (version 8.5.17), which will be located centrally
at IPM with restricted access. Data queries will be
automatically generated by RedCap and transferred to
the operational teams in the districts for data quality
monitoring as the study progresses. Data monitoring will
be conducted on a regular basis as defined in the
monitoring plan. The final database will be transferred
to Oxford University.
A statistical analysis plan will be prepared prior to the
receipt of any data by the trial statistician.
The management, reporting processes and data storage
within this trial will comply with the requirements of
European Directive (reference 2016/679, “GDPR
Directive”) on data protection which is translated into
English law by the “Data Protection Act” of May 2018, the
Good Clinical Practices of the GCP-ICH, and CIOMS.
Confidentiality {27}
All the systems used for data management comply with
the GCP-ICH and CIOMS recommendations as well as
the European Directive (reference 2016/679, “GDPR Dir-
ective”) on the protection of personal data, which is
translated into English law by the “Data Protection Act”
of May 2018.
Participant confidentiality
Trial staff will ensure that the participants’ anonymity is
maintained. All trial documents will be labelled only with
a trial identification number. Trial samples will be labelled
only with a trial ID. Routine bubo and sputum samples,
which will be analyzed as part of the trial, will be
transferred to IPM as per the standard transfer process.
The routine samples taken from trial patients will be
labelled with a collection label which will not contain a
patient trial identifier. A separate letter will be sent to
IPM containing anonymised collection information and
the patient’s trial ID. This will be used to ensure the
results of sample testing from the lab are collected for the
trial without compromising the patient’s anonymity.
For the purpose of ensuring data integrity and to
facilitate quality assurance, study records will be linked
to clinic files, which include the patient’s name and
other identifying information. Participants’ names will be
recorded confidentially at site in a protected master list
at the time of enrolment to allow for their identification
at follow-up visits. The master list will not be shared
with any other parties involved or not involved in the
trial.
All trial data will be stored in a secure database only
accessible to trial staff. Only members of the trial team
who have completed appropriate data protection
training will have access to the password-protected com-
puter where trial data is stored. Study sponsors and
health authorities will be given controlled access for the
purpose of audit. After the conclusion of the project,
data will be removed from the computers and stored in
a secure location. Any scientific publications or reports
will not identify any patient by name or initials.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Aliquots of blood, bubo aspirates and sputum samples will
be stored initially at the site and then transported to IPM.
Sample custody will be maintained by the investigators,
and decisions regarding the use and transfer of samples to
the research laboratory will be made by the TOC.
Biological research samples will be stored indefinitely, and
approval from the sponsor and/or ethics committees, as
appropriate, will be sought prior to destruction.
Rapid diagnostic test (RDT) for plague at admission
The bubo will be aspirated, and a RDT for plague will be
performed on site. This RDT for the detection of the F1
antigen of Y. pestis is manufactured by IPM. The test
has been used routinely over the past decade and has
been validated for bubonic plague. Site staff, clinical
research associates and clinical study nurses will be
trained on the use and interpretation of the RDT before
the start of the study and during annual retraining.
At the central plague laboratory (CPL) level
The remaining bubo aspirate will be stored in Cary Blair
transport medium, packed according to the required
safety level using the materials already provided (triple
packaging), then sent to the CPL at IPM for a second
RDT analysis as well as for molecular and bacteriological
diagnosis. Molecular diagnosis will first be performed by
real-time PCR (qPCR) targeting 2 fragments of the pla
and caf-1 genes of Y. pestis, and only samples with in-
conclusive results will be confirmed by conventional
PCR (cPCR) targeting 3 genes pla, caf-1 and inv1100.
Bacteriology will be done with direct culture and ampli-
fication in mice followed by biochemical identification of
the suspected strain by API 20E and by bacteriophage
lysis test, then antibiotic susceptibility testing of each Y.
pestis isolated strain according to the Kirby Bauer
method interpreted according to the CLSI reference.
Sputum samples will not be tested on site with RDT
but will be sent directly to the CPL. Biological results
will be sent back to the physician responsible for the
patient.
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Malaria
A malaria RDT will be performed on all patients at
admission.
Serology
A 4-ml venous blood sample will be taken at admission
(D1), D11 and D21 for plague serology (for children, a
2-ml venous blood sample will be taken at these time
points). In addition, for subjects with positive serology at
D21, serological follow-up will be carried out at 3
months (M3) after their inclusion. Two types of sero-
logical techniques will be performed: serology by
immuno-enzymatic assay method (ELISA, anti-F1 anti-
bodies, IgG) which is validated and will be performed at
the CPL, and serological analysis by xMAP-Luminex
multiplex technique (Magpix) to simultaneously detect
antibodies (IgM and IgG) directed against several Y. pes-
tis antigens will be performed at the immunology of in-
fectious diseases unit (IMI) at IPM. A serological test
(on magnetic beads, XMAP-Luminex) to detect and
quantify the F1 circulating antigen of Y. pestis will also
be performed. Only anti-F1 IgG ELISA technique will be
considered for case classification.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Primary endpoint analysis
The final classification of cases will take into account all
clinical and biological data in accordance with WHO
recommendations adapted in 2017 with the introduction
of qPCR as a diagnostic tool [3, 11].
The data will be analyzed using four analysis
populations: (i) intention to treat (ITT), (ii) intention to
treat infected (ITTI), (iii) per-protocol (PP) and (iv) per-
protocol infected (PPI). Intention to treat infected (ITTI)
will be the primary analysis population. An infected pa-
tient is a confirmed or probable case. A case is probable
if the RDT or qPCR or serology (anti-F1 IgG ELISA) is
positive but without evidence of seroconversion or a
fourfold increase in antibody titre. A case is confirmed if
the RDT and qPCR are positive or if the culture is posi-
tive or if there has been a seroconversion or a fourfold
increase in antibody titre on two separate serological
samples (either between D1 and D11, between D11 and
D21 or between D1 and D21).
The criteria for exclusion from the per-protocol ana-
lysis population will be specified in advance in the statis-
tical analysis plan (SAP). The proportion of patients who
meet the pre-established definition of therapeutic re-
sponse in the streptomycin plus ciprofloxacin group will
be subtracted from the proportion of patients who meet
the pre-established definition of therapeutic response in
the ciprofloxacin group. A positive difference in
proportions would imply a higher response in patients
treated with ciprofloxacin, compared to streptomycin
plus ciprofloxacin, and a negative difference would imply
a lower response in patients treated with ciprofloxacin.
If the lower limit of the one-sided 2.5% confidence inter-
val (CI) around the difference in proportions is not less
than − 0.15, ciprofloxacin will be considered non-inferior
to streptomycin plus ciprofloxacin.
Analysis of secondary endpoints
Descriptive summaries of the data will be provided by
randomization arm for the pre-specified secondary out-
comes. The data will be summarized by randomization
arm using the mean (95% Cl) and median (interval) for
continuous or discrete data and raw data with percent-
ages and 95% CIs for binary variables. The average time
to resolution of fever and pain at the bubo site will also
be summarized.
Interim analyses {21b}
No formal interim analysis is planned. It is unlikely that
the trial can be stopped prematurely, as a smaller sample
will not provide the precision required to demonstrate
non-inferiority within the pre-specified margin.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
No additional analyses are planned.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Missing data handling: primary endpoint
If a patient has had a resolution of fever and shows a ≥
25% reduction in bubo size on or after day 4, but is lost
for follow-up before day 11, he or she will be considered
to have had a therapeutic response.
Protocol deviations
Any deviations from the protocol will be fully
documented on a protocol deviation form that will be
sent to the sponsor and stored in the trial master file
and on site in the study site file.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
There are currently no plans to grant public access to
the full protocol, participant-level dataset or the statis-
tical code.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
IPM will jointly coordinate the trial with the sponsor,
the University of Oxford.
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As well as a central trial coordination team to
coordinate the day-to-day activities of the trial, IPM
will deploy one clinical research associate and two
clinical study nurses to each district who will assist
the sites with the recruitment, data collection and
conduct monitoring activities. IPM will also be pri-
marily responsible for data management but sup-
ported by the University of Oxford.
The University of Oxford will coordinate the sponsor
activities, coordinate the trial committees and provide
day-to-day management and oversight of the trial.
The TOC is coordinated by the University of Oxford
and is composed of members from each of the study
partners to review the operational management of the
trial and discuss any urgent matters related to trial
conduct as and when they arise. The group meets on a
weekly basis to discuss study progress.
The Trial Steering Committee provides overall
supervision for the trial on behalf of the trial sponsor
and to ensure that the study/trial is conducted according
to the guidelines for Good Clinical Practice (GCP) and
all relevant regulations and local policies.
A Data Safety Monitoring Board has also been
established to maintain oversight of patient safety and
data integrity within the trial.
Composition of the data monitoring committee, its role
and reporting structure {21a}
An independent Data Safety Monitoring Board (DSMB)
has been established to safeguard the interests of trial
participants, to assess the safety of the interventions
during the trial and to assist and advise the principal
investigator (PI) so as to protect the validity and
credibility of the trial.
The DSMB will meet remotely (1) upon the opening
of the trial, (2) at the end of each plague season and (3)
at the end of the trial.
DSMB members:
 Paul Mead, Chief of the Bacterial Diseases Branch
(BDB), Division of Vector-Borne Diseases (DVBD),
National Center for Emerging and Zoonotic Infec-
tious Diseases (NCEZID), Centres for Disease Con-
trol and Prevention
 Professor David Lalloo, Director Liverpool School of
Tropical Medicine and Professor of Tropical
Medicine, Liverpool School of Tropical Medicine,
Pembroke Place Liverpool, L3 5QA, UK
 Professor Julie A Simpson, Head of Biostatistics
Unit/Deputy Head of School, Centre for
Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of
Melbourne, Victoria 3010, Australia
Adverse event reporting and harms {22}
Streptomycin and ciprofloxacin are approved drugs with
well-established safety profiles. Serious adverse events/
serious adverse reactions (SAEs/SARs) and suspected
unexpected serious adverse reactions (SUSARs) will be
reported in accordance with the international guidelines
and applicable national legislation.
All adverse events (AEs) observed or reported by the
patient should be recorded on the AE form within the
CRF.
In the event of an adverse event or reaction, the
investigator is responsible for providing an appropriate
medical response, providing a causality assessment and
monitoring the progress of the AE until it has resolved.
In the event that an adverse event is deemed serious,
according to the international definition (ICH), it should
be notified immediately to IPM via the SAE report form
within 48 h of the site becoming aware of the event.
Newly arising SAEs must be reported from the point of
consent until D21. All SAEs must be followed up by the
site until resolution (including when resolution occurs
after D21).
The following events, which are either classified as
treatment evaluation criteria or inclusion criteria, are
exempt from reporting as an SAE:
 Respiratory symptoms (cough, tachypnea,
haemotysis)
 Intestinal symptoms (diarrhoea, vomiting)
 Fever
 Bubo
 Pain at bubo’s site
In addition, the following circumstances should not be
notified to the sponsor:
 Routine examination
 Medical/surgical/hospital procedure planned before
inclusion
 A condition present before inclusion or discovered
at inclusion (e.g. malaria discovered at inclusion and
requiring hospitalization)
All SAEs/SARs reported to IPM will be notified to the
sponsor within one business day and will be reviewed
and evaluated by two clinical reviewers. If the reviewers
have concerns about the SAEs submitted, an emergency
meeting of the DSMB and the TOC will be convened to
discuss the management of the SAE and the potential
impact on the trial.
All SUSARs will be reported to the Centre National de
Pharmacovigilance in Madagascar within 7 days for fatal
or life-threatening reports and within 15 days for other
serious, unexpected SARs for all initial reports.
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Frequency and plans for auditing trial conduct {23}
None.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
All protocol amendments will be discussed by the TOC
which includes members from each of the study
partners ahead of submission to the respective ethics
committees. It is the responsibility of each institution to
obtain their own ethical approvals. Only once all ethical
approvals have been obtained will the amendment be
implemented. It will be the responsibility of IPM to
disseminate the changes to the protocol to participating
sites.
Dissemination plans {31a}
The principal publication of the study will be in the name
of the investigators with full credit assigned to all
collaborating investigators, research coordinators and
institutions. Oral or written communications will
acknowledge all trial stakeholders, either in the list of
authors or in the acknowledgements, depending on their
respective contributions to the trial and the presentations
made. A drafting committee will be formed at the time of
data analysis. The order of authors at publication will be
equally contributed, by the importance of contribution or
in alphabetical order. Results from the trial will be
published in open-access journals, and the data will be
available for sharing.
Discussion
Conducting clinical trials of plague is operationally
challenging, mostly because cases occur in rural places
with difficult access to health facilities, especially
because cases occur mostly during the rainy season, and
are scattered over a vast territory. Communication and
network coverage may be erratic, and security issues
may also occur. This requires adequately staffed, well-
trained study teams to be deployed over a number of
peripheral health facilities, with logistical challenges and
inherent high costs. This, plus the fact that drugs are
registered for plague (based on the ‘animal rule’) and
that national and international guidelines exist (based on
empirical regimens), along with the general lack of fund-
ing options for plague, has essentially discouraged the
conduct of treatment trials.
Trial status
Protocol version number: 2.9
Protocol date: 27 September 2019
Recruitment start date: planned February 2020
Planned recruitment end date: March 2023
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